Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

VolitionRx

MCap

USD76m

Last close

USD0.81

▲ 0.14 (20.90%)

Canyon Resources

MCap

AUD262m

Last close

AUD0.19

▲ 0.02 (12.12%)

Immix Biopharma

MCap

USD51m

Last close

USD1.82

▲ 0.12 (7.06%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Sequana Medical – executive interview

Sequana Medical – executive interview

Sequana Medical — 3 videos in collection

More on this equity

Sequana Medical is a Belgian commercial-stage medical device company that uses its proprietary alfapump and Direct Sodium Removal (DSR) technologies to develop innovative treatments for diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure. The alfapump is CE marked for refractory ascites and is in a pivotal North American study covering this indication.

In this interview, chief executive officer Ian Crosbie describes the commercial opportunities for the alfapump and DSR platforms in areas of unmet medical need, highlights the company’s recent activities and clinical results and provides an overview of key upcoming catalysts and milestones.

< Previous

Next >

You may also be interested in these:

Healthcare

26.01.24

Sequana Medical - executive interview

Healthcare

15.11.22

Sequana Medical – Executive Interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free